SCHEMBL19869973

SCHEMBL19869973

Cc1cc(Br)cc(C)c1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 1/20 0.45
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.41
GPR119 Q8TDV5 2/20 0.41
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KCNH2 Q12809 1/20 0.41
SCD5 Q86SK9 1/20 0.41
SETD7 Q8WTS6 1/20 0.40
F13A1 P00488 1/20 0.40
TGM2 P21980 1/20 0.40
TGM1 P22735 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19869962 0.90 LMNA (0.46) LMNAKMT2AMEN1POLBSMN1; SMN2
SCHEMBL16155915 0.84 MEN1 (0.47) LMNAKMT2AMEN1POLBUSP2
SCHEMBL23783345 0.83 MEN1 (0.46) LMNAKMT2AMEN1POLBUSP2
SCHEMBL24847099 0.83 LMNA (0.48) LMNAKMT2AMEN1USP2SMN1; SMN2
SCHEMBL25874513 0.83 LMNA (0.47) LMNAKMT2AMEN1POLBGPR119
SCHEMBL17572260 0.82 KMT2A (0.51) LMNAKMT2AMEN1POLBSMN1; SMN2
SCHEMBL30496267 0.81 POLB (0.47) LMNAKMT2AMEN1POLBMAPT
SCHEMBL25237261 0.81 POLB (0.47) LMNAKMT2AMEN1POLBMAPT
SCHEMBL19869966 0.80 KMT2A (0.57) LMNAKMT2AMEN1POLBALDH1A1
SCHEMBL20451482 0.79 KMT2A (0.57) KMT2AMEN1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1902/4885KMT2A 1308/4885MEN1 1894/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1745/4885KMT2A 1279/4885MEN1 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.